According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.

Fintel reports that on June 2, 2025, JP Morgan downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Overweight to Neutral. Analyst Price Forecast Suggests 0.02% Downside As of ...

Sanofi to acquire Blueprint Medicines for about $9.1B The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Fintel reports that on June 4, 2025, Citigroup upgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Sell to Neutral. Analyst Price Forecast Suggests 0.05% Upside As of June 2, 2025 ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and ...

Blueprint Medicines Corporation (NASDAQ:BPMC), a commercial-stage biotechnology company specializing in precision therapies for cancer and rare diseases, has been making significant strides in the ...